Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review - Takeaways - MDSpire

Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review

  • By

  • Fang Lu

  • Yi Li

  • Yaqian Zhu

  • Wenkang Zong

  • Fang Zhao

  • Yongxiang Zhang

  • Liheng Yang

  • Yuechuan Li

  • July 6, 2026

  • 0 min

Share

  • 1

    Two patients with non-small cell lung cancer developed immune-related pancytopenia after treatment with tislelizumab and chemotherapy.

  • 2

    Both cases presented with severe neutropenia, thrombocytopenia, and anemia, with additional complications like hepatitis and mucositis.

  • 3

    Management included granulocyte-stimulating factor, thrombopoietin, transfusions, and corticosteroids, but grade 4 neutropenia persisted.

  • 4

    Both patients ultimately died from multiple organ dysfunction syndrome, highlighting the severity of hematologic immune-related adverse events.

  • 5

    Hematologic irAEs are rare but can occur with immune checkpoint inhibitors, necessitating careful monitoring and prompt intervention.

Original Source(s)

Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review

  • by Fang Lu, Yi Li, Yaqian Zhu, Wenkang Zong, Fang Zhao, Yongxiang Zhang, Liheng Yang, Yuechuan Li

  • July 6, 2026

Related Content

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review